---
title: "Watch live: Rethinking Psychedelic Treatment for America's Mental Health Crisis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286901819.md"
description: "A forum hosted by The Hill and Definium Therapeutics will discuss the potential of psychedelic treatments for mental health issues, addressing the economic impact of mental illness in the U.S. and the need for innovative therapies. With several psychedelic medicines in late-stage trials and receiving FDA Breakthrough Therapy Designation, the event aims to inform lawmakers and advocates on the regulatory landscape and necessary actions to support patients."
datetime: "2026-05-19T11:13:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286901819.md)
  - [en](https://longbridge.com/en/news/286901819.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286901819.md)
---

# Watch live: Rethinking Psychedelic Treatment for America's Mental Health Crisis

Psychiatry is at an inflection point — and the stakes are high. Mental illness costs the U.S. economy more than $280 billion annually, drives veteran suicide rates, and places mounting strain on everything from emergency rooms to the workforce. Yet many of today’s medicines have not advanced in decades despite the rising prevalence and unmet need.

For the one in five Americans living with a mental health disorder and veterans who face disproportionally high suicide rates and do not respond to conventional treatments, the gap between what medicine promises and what it delivers has never been more consequential.

But change is underway. A new wave of rigorous clinical science is unlocking the therapeutic potential of psychedelic medicines and opening new routes for brain health that could redefine what treatment success looks like.

Psychedelic medicines are advancing through late-stage clinical trials, with several investigational candidates earning FDA Breakthrough Therapy Designation for disorders including anxiety and depression.

Join The Hill, in partnership with Definium Therapeutics, for a timely mental health policy forum convening lawmakers, clinical researchers, and advocates to explore what science tells us, what the regulatory landscape requires, and what actions Congress can take to ensure that patients are not left behind.

The event is scheduled to begin at 8:30 a.m. ET.

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)

## Related News & Research

- [Bergman: ‘The time is now’ to push for breakthroughs in psychedelic treatments](https://longbridge.com/en/news/286946328.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy](https://longbridge.com/en/news/286655317.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)
- [Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy | AVAI Stock News](https://longbridge.com/en/news/287067719.md)